Latvia - Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry
Since 2014, Latvia Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry was up 6.9% year on year. With $7.56 Million PPP in 2019, the country was number 65 comparing other countries in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry. Latvia is overtaken by Romania, which was number 64 with $26.52 Million PPP and is followed by Slovakia at $4.29 Million PPP. United States ranked the highest with $70,565,318,932.39 Million PPP in 2019, +3.3% versus 2018. China, Japan and Germany respectively ranked number 2, 3 and 4 in this ranking. Iceland recorded the best 5 years average growth at +43.9% per year, while Lithuania witnessed the worst performance at -42.6% per year.
Loading...
| Date | Million US Dollars PPP |
|---|---|
| 2019 | 7.56 |
| 2018 | 7.58 |
| 2017 | 8.55 |
| 2016 | 5.67 |
| 2015 | 5.43 |
How does Latvia rank in Business Enterprise Expenditure on R&D Performed in the Pharmaceutical Industry?
| # | 69 Countries | Million US Dollars PPP | Last | YoY | 5‑years CAGR | ||
|---|---|---|---|---|---|---|---|
| 1 |
#1
United States
|
70,565,318,932.39 | 2019 | +3.3 % | +4.5 % | View data | |
| 2 |
#2
China
|
13,956,388,273.35 | 2019 | +4.5 % | +6.1 % | View data | |
| 34 |
#34
Lithuania
|
1,065,743.71 | 2019 | -29.1 % | -42.6 % | View data | |
| 65 |
#65
Latvia
|
7.56 | 2019 | -0.3 % | +6.8 % | View data | |